COHBAR INC - CWBR STOCK NEWS

CohBar, Inc. (NASDAQ: CWBR), a clinical-stage biotechnology company, announced the appointment of Dr. Effie Tozzo as an independent director, effective July 11, 2022. Dr. Tozzo brings extensive experience in drug development from roles in both biotechnology and pharmaceutical companies. Her expertise is expected to bolster CohBar’s efforts in advancing its preclinical and clinical programs, particularly leveraging the mitochondrial genome for new therapeutics. The company focuses on chronic and age-related diseases with limited treatment options.

CohBar, Inc. (NASDAQ: CWBR), a clinical-stage biotechnology company, announced that CEO Dr. Joseph Sarret will participate in two key conferences this June. At the BIO International Convention in San Diego, he will present on June 14 at 5:00 PM PT. Additionally, at the 4th Annual Longevity Therapeutics Summit in San Francisco, he will join a panel discussion on June 30 at 10:30 AM PT focusing on investment strategies in longevity. CohBar specializes in developing therapies targeting chronic and age-related diseases leveraging mitochondrial peptides.

CohBar, a clinical-stage biotechnology company (NASDAQ: CWBR), announced its virtual participation in the 2022 H.C. Wainwright Global Investment Conference.

Dr. Joseph Sarret, CEO, will present a company overview starting May 24, 2022, at 7:00 a.m. ET. The presentation will be available for on-demand listening at the conference website and on CohBar's Investors section.

The company focuses on developing therapeutics targeting chronic and age-related diseases through mitochondrial peptides, emphasizing inflammation and fibrosis.

CohBar, Inc. (NASDAQ: CWBR) announced its first-quarter financial results for 2022 and outlined key corporate developments. The company reported cash and investments of $23.5 million, a decrease from $26.2 million at year-end 2021. Despite a net loss of $3.3 million ($0.04 per share), this was an improvement from a $4.0 million loss in the same period last year. Notably, CohBar received a 180-day extension from Nasdaq to remain compliant with listing requirements and expanded patent coverage for its drug candidate, CB4211, targeting obesity.

CohBar (NASDAQ: CWBR), a clinical-stage biotechnology firm, has received a 180-day extension from the Nasdaq Capital Market to regain compliance with the minimum bid price requirement, now due by November 7, 2022. At the upcoming Annual Meeting on June 15, 2022, CohBar will propose a reverse stock split up to one-for-thirty and an increase in authorized shares. CEO Dr. Joseph Sarret emphasized the importance of maintaining the Nasdaq listing for capital access and shareholder value, urging support for the reverse split to help achieve this goal.

CohBar, Inc. (NASDAQ: CWBR) will release its 2022 first-quarter financial results after market close on May 16, 2022. Following the release, management will conduct a conference call and webcast at 5:00 p.m. ET to discuss the company's performance and business updates. Interested parties can access the call via phone or through the company's website. The audio replay will be available from 8:00 p.m. ET on the same day until June 6, 2022. CohBar focuses on developing therapeutics targeting chronic and age-related diseases using mitochondrial peptides.

CohBar, Inc. (NASDAQ: CWBR) reported its Q4 and full-year 2021 results on March 29, 2022. The company highlighted significant growth, including positive data from its first human study and the nomination of its second clinical candidate. CohBar plans to focus on three key areas: advancing its IPF program CB5138-3, discovering new peptide families via the Mito+ platform, and securing a partner for CB4211's development. Financial metrics showed a net loss of $2.8 million for Q4 2021, an improvement from $4.7 million in Q4 2020, and cash and investments increased to $26.2 million.

CohBar, Inc. (NASDAQ: CWBR) will release its 2021 fourth quarter and full year financial results on March 29, 2022, after market close. A conference call and webcast is scheduled for 5:00 p.m. ET on the same day, providing updates on the company's business. Interested participants can access the call via dial-in or through the CohBar website. An audio replay will be available from 8:00 p.m. ET on March 29 until 11:59 p.m. ET on April 19, 2022.

CohBar, Inc. (NASDAQ: CWBR), a clinical-stage biotechnology firm, announced that its CEO, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright BIOCONNECT Conference from January 10-14, 2022. The conference will be held virtually, and interested parties can access the presentation via a designated webcast link. CohBar focuses on developing therapeutics leveraging the power of mitochondria and peptides for chronic and age-related diseases. Its lead compound, CB4211, targets NASH and obesity, having completed successful clinical trials.